Idexx Laboratories (IDXX) EBIT (2009 - 2025)

Idexx Laboratories' EBIT history runs 17 years deep, the most recent figure standing at $1.4 billion for FY2025.

• In Q1 2026, EBIT rose 14.55% year-over-year to $362.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 22.7% YoY), while the FY2025 annual figure was $1.4 billion, up 20.53% from the prior year.
• EBIT was $1.4 billion for FY2025 at Idexx Laboratories, up from $1.1 billion in the prior year.
• In the past five years, EBIT ranged from a high of $1.4 billion in FY2025 to a low of $898.8 million in FY2022.
• Historically, EBIT has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2023.
• The sharpest annual moves came in 2021 and 2022: EBIT jumped 34.2% in 2021, then retreated 3.57% in 2022.
• A 5-year view of EBIT shows it stood at $932.0 million in 2021, then dropped by 3.57% to $898.8 million in 2022, then grew by 22.07% to $1.1 billion in 2023, then gained by 2.84% to $1.1 billion in 2024, then grew by 20.53% to $1.4 billion in 2025.
• The last three EBIT figures came in at $1.4 billion (FY2025), $1.1 billion (FY2024), and $1.1 billion (FY2023), per Business Quant data.